199 related articles for article (PubMed ID: 29457966)
1. Combined Treatment with Valproic Acid and 5-Aza-2'-Deoxycytidine Synergistically Inhibits Human Clear Cell Renal Cell Carcinoma Growth and Migration.
Xi W; Chen X; Sun J; Wang W; Huo Y; Zheng G; Wu J; Li Y; Yang A; Wang T
Med Sci Monit; 2018 Feb; 24():1034-1043. PubMed ID: 29457966
[TBL] [Abstract][Full Text] [Related]
2. Combination of metformin and valproic acid synergistically induces cell cycle arrest and apoptosis in clear cell renal cell carcinoma.
Zhang X; Zhang X; Huang T; Geng J; Liu M; Zheng J
Int J Clin Exp Pathol; 2015; 8(3):2823-8. PubMed ID: 26045790
[TBL] [Abstract][Full Text] [Related]
3. Valproic acid sensitizes metformin-resistant human renal cell carcinoma cells by upregulating H3 acetylation and EMT reversal.
Wei M; Mao S; Lu G; Li L; Lan X; Huang Z; Chen Y; Zhao M; Zhao Y; Xia Q
BMC Cancer; 2018 Apr; 18(1):434. PubMed ID: 29665787
[TBL] [Abstract][Full Text] [Related]
4. Decitabine induces G2/M cell cycle arrest by suppressing p38/NF-κB signaling in human renal clear cell carcinoma.
Shang D; Han T; Xu X; Liu Y
Int J Clin Exp Pathol; 2015; 8(9):11140-8. PubMed ID: 26617834
[TBL] [Abstract][Full Text] [Related]
5. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S
Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331
[TBL] [Abstract][Full Text] [Related]
6. Valproic acid, in combination with all-trans retinoic acid and 5-aza-2'-deoxycytidine, restores expression of silenced RARbeta2 in breast cancer cells.
Mongan NP; Gudas LJ
Mol Cancer Ther; 2005 Mar; 4(3):477-86. PubMed ID: 15767557
[TBL] [Abstract][Full Text] [Related]
7. 5-aza-2'-deoxycytidine improves the sensitivity of endometrial cancer cells to progesterone therapy.
Hu Q; Yu L; Chen R; Wang YL; Ji L; Zhang Y; Xie Y; Liao QP
Int J Gynecol Cancer; 2012 Jul; 22(6):951-9. PubMed ID: 22683940
[TBL] [Abstract][Full Text] [Related]
8. Valproic acid in the complex therapy of malignant tumors.
Hrebackova J; Hrabeta J; Eckschlager T
Curr Drug Targets; 2010 Mar; 11(3):361-79. PubMed ID: 20214599
[TBL] [Abstract][Full Text] [Related]
9. Sodium valproate and 5-aza-2'-deoxycytidine differentially modulate DNA demethylation in G1 phase-arrested and proliferative HeLa cells.
Rocha MA; Veronezi GMB; Felisbino MB; Gatti MSV; Tamashiro WMSC; Mello MLS
Sci Rep; 2019 Dec; 9(1):18236. PubMed ID: 31796828
[TBL] [Abstract][Full Text] [Related]
10. Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation.
Reu FJ; Bae SI; Cherkassky L; Leaman DW; Lindner D; Beaulieu N; MacLeod AR; Borden EC
J Clin Oncol; 2006 Aug; 24(23):3771-9. PubMed ID: 16801630
[TBL] [Abstract][Full Text] [Related]
11. Valproic acid inhibits proliferation of HER2-expressing breast cancer cells by inducing cell cycle arrest and apoptosis through Hsp70 acetylation.
Mawatari T; Ninomiya I; Inokuchi M; Harada S; Hayashi H; Oyama K; Makino I; Nakagawara H; Miyashita T; Tajima H; Takamura H; Fushida S; Ohta T
Int J Oncol; 2015 Dec; 47(6):2073-81. PubMed ID: 26497673
[TBL] [Abstract][Full Text] [Related]
12. Valproic acid: growth inhibition of head and neck cancer by induction of terminal differentiation and senescence.
Gan CP; Hamid S; Hor SY; Zain RB; Ismail SM; Wan Mustafa WM; Teo SH; Saunders N; Cheong SC
Head Neck; 2012 Mar; 34(3):344-53. PubMed ID: 21438066
[TBL] [Abstract][Full Text] [Related]
13. In Vitro Effect of the Histone Deacetylase Inhibitor Valproic Acid on Viability and Apoptosis of the PLC/PRF5 Human Hepatocellular Carcinoma Cell Line.
Sanaei M; Kavoosi F; Roustazadeh A; Shahsavani H
Asian Pac J Cancer Prev; 2018 Sep; 19(9):2507-2510. PubMed ID: 30256044
[TBL] [Abstract][Full Text] [Related]
14. Demethylating agent 5-aza-2'-deoxycytidine enhances susceptibility of renal cell carcinoma to paclitaxel.
Shang D; Ito N; Kamoto T; Ogawa O
Urology; 2007 May; 69(5):1007-12. PubMed ID: 17482960
[TBL] [Abstract][Full Text] [Related]
15. Alterations of the gene expression profile in renal cell carcinoma after treatment with the histone deacetylase-inhibitor valproic acid and interferon-alpha.
Juengel E; Bhasin M; Libermann T; Barth S; Michaelis M; Cinatl J; Jones J; Hudak L; Jonas D; Blaheta RA
World J Urol; 2011 Dec; 29(6):779-86. PubMed ID: 20640575
[TBL] [Abstract][Full Text] [Related]
16. Anti-proliferative potential of Glucosamine in renal cancer cells via inducing cell cycle arrest at G0/G1 phase.
Wang LS; Chen SJ; Zhang JF; Liu MN; Zheng JH; Yao XD
BMC Urol; 2017 May; 17(1):38. PubMed ID: 28558682
[TBL] [Abstract][Full Text] [Related]
17. Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma.
Bensaid D; Blondy T; Deshayes S; Dehame V; Bertrand P; Grégoire M; Errami M; Blanquart C
Clin Epigenetics; 2018; 10():79. PubMed ID: 29946373
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic modifiers 5-aza-2'-deoxycytidine and valproic acid differentially change viability, DNA damage and gene expression in metastatic and non-metastatic colon cancer cell lines.
Ghecham A; Senator A; Pawlowska E; Bouafia W; Błasiak J
Acta Biochim Pol; 2019 Jul; 66(3):355-360. PubMed ID: 31284710
[TBL] [Abstract][Full Text] [Related]
19. Ginsenoside Rg3 inhibits renal cell carcinoma cell migration, invasion, colony formation, and tube formation and enhances apoptosis through promoting the DNA demethylation and histone acetylation.
Ma Z; Zuo Y; Wang W
J Pharm Pharmacol; 2023 Jan; 75(1):76-86. PubMed ID: 36264186
[TBL] [Abstract][Full Text] [Related]
20. Antileukemia activity of the combination of 5-aza-2'-deoxycytidine with valproic acid.
Yang H; Hoshino K; Sanchez-Gonzalez B; Kantarjian H; Garcia-Manero G
Leuk Res; 2005 Jul; 29(7):739-48. PubMed ID: 15927669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
